Total HSPC yields, with extended CD34⁺ HSPC and T-cell immunophenotyping. (A) Total CD34⁺ HSPC yields in HLA–matched sibling donors mobilized with 1 injection of motixafortide (1.0 mg/kg) and up to 2 LPs. (B) Total CD34⁺ HSPC yields in HLA–matched sibling donors or haploidentical donors mobilized with 1 injection of motixafortide (1.25 mg/kg) and up to 2 LPs. (C) Inhibition of anti-CXCR4 monoclonal antibody clone 12G5 binding to motixafortide-mobilized CD34⁺ HSPCs. CXCR4 expression on CD34⁺ HSPCs obtained from the day 1 apheresis product was determined via flow cytometery, using anti-CXCR4 clones 12G5 and 1D9. (D) Extended HSPC immunophenotyping of CD34⁺ purified cells from apheresis product mobilized with motixafortide with relative proportions of HSC/CMPs, granulocytic myeloid progenitors and common lymphoid progenitors, and pre-pDCs. (E,G) Pan-mobilization of myeloid and lymphoid subsets by using motixafortide. The PB concentration of each subset was calculated before and 3 hours after BL-804 treatment (before initiation of LP) and relative change calculated. (F,H) The expression of CXCR4 on each subset at baseline was determined via flow cytometry, using anti-CXCR4 clone 12G5.